1. Home
  2. CSWC vs NRIX Comparison

CSWC vs NRIX Comparison

Compare CSWC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSWC
  • NRIX
  • Stock Information
  • Founded
  • CSWC 1961
  • NRIX 2009
  • Country
  • CSWC United States
  • NRIX United States
  • Employees
  • CSWC N/A
  • NRIX N/A
  • Industry
  • CSWC Textiles
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSWC Consumer Discretionary
  • NRIX Health Care
  • Exchange
  • CSWC Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • CSWC 1.0B
  • NRIX 1.1B
  • IPO Year
  • CSWC N/A
  • NRIX 2020
  • Fundamental
  • Price
  • CSWC $20.94
  • NRIX $9.58
  • Analyst Decision
  • CSWC Hold
  • NRIX Strong Buy
  • Analyst Count
  • CSWC 3
  • NRIX 17
  • Target Price
  • CSWC $22.50
  • NRIX $30.71
  • AVG Volume (30 Days)
  • CSWC 487.8K
  • NRIX 895.9K
  • Earning Date
  • CSWC 05-14-2025
  • NRIX 07-10-2025
  • Dividend Yield
  • CSWC 12.22%
  • NRIX N/A
  • EPS Growth
  • CSWC N/A
  • NRIX N/A
  • EPS
  • CSWC 1.43
  • NRIX N/A
  • Revenue
  • CSWC $198,464,000.00
  • NRIX $56,417,000.00
  • Revenue This Year
  • CSWC $17.45
  • NRIX $15.43
  • Revenue Next Year
  • CSWC $10.35
  • NRIX N/A
  • P/E Ratio
  • CSWC $14.75
  • NRIX N/A
  • Revenue Growth
  • CSWC 17.51
  • NRIX N/A
  • 52 Week Low
  • CSWC $17.46
  • NRIX $8.18
  • 52 Week High
  • CSWC $27.23
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • CSWC 56.31
  • NRIX 38.72
  • Support Level
  • CSWC $19.89
  • NRIX $9.02
  • Resistance Level
  • CSWC $20.26
  • NRIX $10.38
  • Average True Range (ATR)
  • CSWC 0.41
  • NRIX 0.57
  • MACD
  • CSWC 0.18
  • NRIX -0.04
  • Stochastic Oscillator
  • CSWC 75.86
  • NRIX 20.66

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: